Clinical Trial Update: A Study of Oral Gimatecan in Platinum-Resistant Epithelial Ovarian, Fallopian Tube or Peritoneal Cancer [Phase 2]

View source ↗

Summary

Phase 2 study evaluating oral gimatecan in platinum-resistant epithelial ovarian cancer and related abdominal cancers is ongoing with unknown current status.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Epithelial Ovarian Cancer
• Fallopian Tube Cancer
• Peritoneal Cancer

Drugs mentioned

• gimatecan (gimatecan)

Snippet

Sponsor: Lee's Pharmaceutical Limited | Conditions: Epithelial Ovarian Cancer, Fallopian Tube Cancer | Phase 2 | Status: UNKNOWN